Clinical Effects of the Sequential Therapy of TAE and Oxaliplatin,Raltitrexed Plus Anlotinib in Treating the Patients with Advanced Primary Liver Cancer
HAN Chaowen
LIANG Xiuqun
SHEN Yongqi
LI Kaixuan
KANG Zhongqiang
HE Sha
ZHANG Qing
XIE Shuqiong
OU Huixu
WEI Jinlian
Abstract：Objective To evaluate the efficacy and toxicity of the sequential therapy of transcatheterarterial embolization(TAE)and oxaliplatin,raltitrexed plus anlotinib in treating the patients with advanced primary liver cancer(PLC).Methods Eighty-one patients with advanced PLC admitted to 4 cancer center from January 2018 to June 2020 with recurrence or progression after first-line treatment were selected,according to the wishes of the patient or the family,40 patients accepted the sequential therapy of TAE and raltitrexed,oxaliplatin plus anlotinib.Results The objective remission rate(ORR)of 40 patients was 35.0％,disease control rate(DCR)was 82.5％,median overall survival(mOS)was 18.2 months,median progression-free survival(mPFS)was 8.6 months,and one year survival rate(SR)was 52.5％.The main side effects(Ⅰ-Ⅳ)were digestive tract reaction(40.0％),myelosuppression(67.5％),hepatotoxicity(27.5％),peripheral neurotoxicity(25.0％),hypertension(22.5％),hoarseness(35.0％),skin reaction(52.5％)and fever(20.0％).The severe side effect(Ⅲ-Ⅳ)were digestive tract reaction(2.5％),myelosuppression(27.5％)and fever(2.5％).Most of these side effects can be remitted by the positive treatment.Conclusion The sequential therapy of TAE and oxaliplatin,raltitrexed plus anlotinib is safe and effective to the patients with advanced PLC.
Keywords：primary liver canceroxaliplatinraltitrexedtranscatheterarterial embolizationanlotinib
Publication Date：2023-12-31
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：5( 4425-4429 )